Jinling Pharmaceutical (000919.SZ): Its subsidiary, Ipratropium Bromide, has obtained a notice of approval for the marketing application of chemical raw materials.
On June 28, Gelunhui reported that Jinling Pharmaceutical (000919.SZ) recently announced that its subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as 'Dongsheng Pharmaceutical'), controlled by Jinling Pharmaceutical Co., Ltd., received the 'Chemical Active Pharmaceutical Ingredient Market Approval Notice' (Notice No. 2024YS00595) issued by the State Drug Administration for its ingredient of ipratropium bromide. Ipratropium bromide is used to relieve bronchospasm and asthma symptoms caused by chronic obstructive pulmonary disease (COPD), and is suitable for the prevention and treatment of asthma, especially for those who cannot tolerate such drugs due to the side effects of beta receptor agonists, such as muscle tremors and tachycardia.
Jinling Pharmaceutical (000919.SZ): As of June 20, 2024, the total number of shareholders of the company is 36,441.
Jinling Pharmaceutical (000919.SZ) stated on the investor interaction platform on June 26 that as of June 20, 2024, there were 36,441 shareholders in the company.
Jinling Pharmaceutical (000919.SZ) 2023 equity distribution: 1 yuan for every 10 shares
Jinling Pharmaceutical (000919.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
Jinling Pharmaceutical (000919.SZ): As of May 10, 2024, the total number of shareholders of the company was 37,991
Gelonghui May 14 | Jinling Pharmaceutical (000919.SZ) said on the investor interactive platform that as of May 10, 2024, the total number of shareholders of the company was 37,991.
Jinling Pharmaceutical (000919.SZ): Currently, major products have not entered national collection
Gelonghui May 9丨Jinling Pharmaceutical (000919.SZ) held a performance briefing on May 9, 2024 to “ask which varieties of the company may enter collection in the future?” The company replied that at present, the company's main products have not been collected by the country. The company will pay close attention to national collection policy trends and proactively respond to possible policy changes.
Why Jinling Pharmaceutical's (SZSE:000919) Shaky Earnings Are Just The Beginning Of Its Problems
A lackluster earnings announcement from Jinling Pharmaceutical Company Limited (SZSE:000919) last week didn't sink the stock price. Our analysis suggests that along with soft profit numbers, investor
Jinling Pharmaceutical (000919.SZ) announced first-quarter results, net profit of 43.5547 million yuan, a year-on-year decrease of 0.09%
According to Zhitong Finance App, Jinling Pharmaceutical (000919.SZ) released its report for the first quarter of 2024. The company's revenue was 747 million yuan, up 5.36% year on year; net profit attributable to shareholders of listed companies was 43.54 million yuan, down 0.09% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 41.424,500 yuan, up 10.14% year on year; basic earnings per share were 0.0849 yuan/share.
Does The Market Have A Low Tolerance For Jinling Pharmaceutical Company Limited's (SZSE:000919) Mixed Fundamentals?
It is hard to get excited after looking at Jinling Pharmaceutical's (SZSE:000919) recent performance, when its stock has declined 6.6% over the past month. We, however decided to study the company's
Jinling Pharmaceutical (000919.SZ) disclosed fixed increase results: NORD Fund, CaiTong Fund, and Cathay Pacific Junan participated
Gelonghui March 28 | Jinling Pharmaceutical (000919.SZ) released a report on the issuance of A-shares to specific targets in 2023, and determined that the issuance price of this issue was 6.36 yuan/share. The final issuance target of this offering was a total of 10 specific targets, including Xingong Group, the controlling shareholder of the company. The number of shares issued was 118 million shares, and the total capital raised was about 750 million yuan.
Jinling Pharmaceutical (000919.SZ): As of March 8, 2024, the total number of shareholders of the company was 39,542
Gelonghui March 12 | Jinling Pharmaceutical (000919.SZ) said on the investor interactive platform that as of March 8, 2024, the total number of shareholders of the company was 39,542.
Jinling Pharmaceutical (000919.SZ): It has built 3 demonstration bases for Chinese herbal medicines with a total of 355 acres
Gelonghui, Feb. 29丨Jinling Pharmaceutical (000919.SZ) said on the investor interactive platform that the company has built 3 demonstration bases for Chinese herbal medicines with a total of 355 acres, located in Pu'er, Yunnan (300 mu per dendrobium) and Fengqiu, Henan (55 mu per honeysuckle).
Jinling Pharmaceutical (000919.SZ): As of February 20, 2024, the total number of shareholders of the company was 40,491
Gelonghui, Feb. 22丨Jinling Pharmaceutical (000919.SZ) said on the investor interactive platform that as of February 20, 2024, the total number of shareholders of the company was 40,491.
Investors One-year Losses Continue as Jinling Pharmaceutical (SZSE:000919) Dips a Further 10% This Week, Earnings Continue to Decline
It's normal to be annoyed when stock you own has a declining share price. But often it is not a reflection of the fundamental business performance. The Jinling Pharmaceutical Company Limited (SZSE:
Jinling Pharmaceutical (000919.SZ): As of January 19, 2024, the total number of shareholders of the company was 4,2092
Gelonghui, January 22丨Jinling Pharmaceutical (000919.SZ) said on the investor interactive platform that as of January 19, 2024, the total number of shareholders of the company was 4,2092.
Jinling Pharmaceutical (000919.SZ): The controlling shareholder, Xingong Group, is a large state-owned enterprise group in Nanjing
Gelonghui, January 15 | Jinling Pharmaceutical (000919.SZ) recently stated during a survey receiving institutional investors that the controlling shareholder of the company, Xingong Group, is a large state-owned enterprise group in Nanjing. It bears the heavy responsibility of promoting the development of advanced manufacturing and strategic emerging industries, financing major industrial development projects and making pioneering investments, and undertakes the important tasks of managing the operation, asset preservation and appreciation of the stability of municipal state-owned industrial enterprises. Currently, the business segments of Xingong Group include new pharmaceuticals and life health, high-end equipment manufacturing, new materials, beauty, and productive services, and fund investment. Directly managed by the Nanjing Municipal State-owned Assets Administration Commission
Jinling Pharmaceutical (000919.SZ): Currently, none of the company's core products are included in the scope of national collection
Gelonghui, January 15 | Jinling Pharmaceutical (000919.SZ) recently said during a survey by institutional investors that none of the company's core products are currently included in the scope of national procurement. The company has always paid attention to trends related to national procurement. On the one hand, it will adapt to industry trends, continue to focus on key product structure and channel coverage, and share resources and synergy with potential varieties; on the other hand, the company will continue to increase investment in R&D, strengthen academic promotion, and actively cultivate new varieties to win a wider market space for the company.
Jinling Pharmaceutical (000919.SZ): Application for issuing shares to specific targets obtained approval from the Securities Regulatory Commission
Gelonghui, January 14, 丨 Jinling Pharmaceutical (000919.SZ) issued an announcement. The company recently received the “Approval to Register Jinling Pharmaceutical Co., Ltd. to issue shares to specific targets” (Securities Regulatory License [2024] No. 41) from the China Securities Regulatory Commission.
Jinling Pharma in Talks to Buy Over 50% Stake in Local Hospital
Jinling Pharmaceutical (SHE:000919) has signed a letter of intent to acquire an over 50% stake in a local hospital in China to strengthen its foothold in the regional healthcare market. The acquisitio
Jinling Pharmaceutical (000919.SZ) plans to directly hold more than 50% of Nanjing Meishan Hospital's shares to resolve competition issues in the industry
Jinling Pharmaceutical (000919.SZ) announced that in order to resolve the issue of Nanjing Xingong Investment Group Co., Ltd. (“Xingong...
Jinling Pharmaceutical (000919.SZ): Plans to acquire funds held by Xingong Group and Zijin Asset Management together exceed 43.60% of the fund share
Gelonghui, January 4 丨 Jinling Pharmaceutical (000919.SZ) announced that in order to establish the company's “dual platform for medicine and medical care”, improve the company's regional medical market layout, and resolve peer competition between Nanjing Meishan Hospital Co., Ltd. (“Nanjing Meishan Hospital”) controlled by Nanjing Xingong Investment Group Co., Ltd. (“Xingong Group”) and the company, the company, Xingong Group, and Nanjing Zijin Asset Management Co., Ltd. (“Zijin Asset Management”), Nanjing Xingong Medical Industry Investment Fund Partnership (“Limited Partnership”) (“Fund” for short) “Partnership”), fund management
No Data